Operator
Good morning, women and gents, and welcome to the Milestone Prescribed drugs Fourth Quarter and 12 months-Finish 2025 Company Replace Convention Name. [Operator Instructions] As a reminder, this convention is being recorded. I’ll now flip the decision over to your host, Michael Wooden of LifeSci Advisors. You might now start your convention.
Michael Wooden
Lifesci Advisors, LLC
Thanks, operator, and good morning, everybody, and welcome to the Milestone Prescribed drugs Full-12 months 2025 Monetary Outcomes and Enterprise Replace Convention Name. Earlier this morning, the corporate issued a press launch offering an summary of its monetary outcomes for the 12 months ended December 31, 2025, and up to date company highlights. The discharge might be accessed on the Buyers and Media part of the corporate’s web site, milestonepharma.com.
Earlier than I start, I might wish to remind everybody that a number of the info offered on this convention name comprises forward-looking statements below the securities legal guidelines. These forward-looking statements contain substantial dangers and uncertainties that would trigger precise scientific applications, future outcomes, progress, timing, performances or achievements to vary materially from these expressed or implied by such forward-looking statements.
These dangers and uncertainties related to Milestone’s enterprise and elements that would trigger or contribute to such variations are described intimately within the firm’s filings with the SEC, together with within the Danger Elements part of the earnings report on Kind 10-Okay
